# Determinants of tuberculosis among adult people living with HIV on antiretroviral therapy at public hospitals in Hawassa City, South Ethiopia

**Authors:** Ahmed Asefa, Habte Bolka, Endrias Markos Woldesemayat

PMC · DOI: 10.3389/fepid.2024.1353760 · 2024-04-04

## TL;DR

This study identifies factors that increase the risk of tuberculosis in HIV patients receiving treatment in Ethiopia.

## Contribution

The study identifies five specific determinants of TB among HIV patients on ART in Hawassa City, Ethiopia.

## Key findings

- Age, residency, and advanced WHO clinical stage increase TB risk.
- Using 3HP prophylaxis reduces TB risk among HIV patients.
- Other opportunistic infections increase TB risk in HIV patients.

## Abstract

The burden of tuberculosis (TB)/HIV co-infection is high in sub-Saharan African countries. The aim of the present study was to identify determinants of TB among people living with HIV (PLHIV) on antiretroviral therapy (ART) at public hospitals in Hawassa City Administration, Sidama Region, Ethiopia.

A facility-based case-control study was conducted between 30 March and 30 April 2023. We employed a systematic random sampling to recruit participants. The cases were all adult PLHIV who developed TB after ART initiation, and the group without TB were all adult PLHIV who did not develop TB after their ART initiation. Data were collected from patients’ medical records using Kobo-tool and then exported to SPSS Version 26 for analysis. A multivariable logistic regression was used to identify the predictors of TB. Statistical significance was defined using the 95% confidence interval (CI).

A total of 124 cases and 249 people without TB participated in the study. In a multivariable logistic regression analysis, we identified five independent determinants of TB. These include age (adjusted odds ratio (AOR) = 2.7; 95% CI 1.4–5.2), patients’ residency (AOR = 6.4; 95% CI 2.8–14.5), WHO clinical stage III or IV (AOR = 6.7; 95% CI 3.2–14.0), isoniazid plus rifapentine (3HP) prophylaxis using (AOR = 0.5; 95% CI 0.2–0.9), and having other opportunistic infections (AOR = 3.6; 95% CI 1.7–7.6).

Several risk factors for TB were identified among PLHIV. Strengthening TB screening in advanced disease conditions, encouraging use of 3HP prophylaxis, and early diagnosis and treatment of opportunistic infections were recommended to reduce the incidence of TB among PLHIV.

## Linked entities

- **Chemicals:** isoniazid (PubChem CID 3767), rifapentine (PubChem CID 135403821), 3HP (PubChem CID 12122)
- **Diseases:** tuberculosis (MONDO:0018076)

## Full-text entities

- **Diseases:** opportunistic infections (MESH:D009894), tuberculosis (MESH:D014376), HIV co-infection (MESH:D015658)
- **Chemicals:** rifapentine (MESH:C018421), 3HP (-), isoniazid (MESH:D007538)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC11025533